The Geographic Atrophy drugs in development market research report provides comprehensive information on the therapeutics under development for Geographic Atrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Geographic Atrophy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Geographic Atrophy and features dormant and discontinued products.
GlobalData tracks 75 drugs in development for Geographic Atrophy by 62 companies/universities/institutes. The top development phase for Geographic Atrophy is preclinical with 45 drugs in that stage. The Geographic Atrophy pipeline has 73 drugs in development by companies and two by universities/ institutes. Some of the companies in the Geographic Atrophy pipeline products market are: Boehringer Ingelheim International, Apellis Pharmaceuticals and Adverum Biotechnologies.
The key targets in the Geographic Atrophy pipeline products market include Complement C5, Complement C3, and Complement Factor I.
The key mechanisms of action in the Geographic Atrophy pipeline product include Complement C5 Inhibitor with six drugs in Pre-Registration. The Geographic Atrophy pipeline products include eight routes of administration with the top ROA being Intravitreal and 13 key molecule types in the Geographic Atrophy pipeline products market including Small Molecule, and Gene Therapy.
Geographic Atrophy overview
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), a progressive eye condition affecting the macula, the central part of the retina responsible for detailed central vision. GA specifically refers to a severe and advanced stage of dry AMD. GA is characterized by the gradual degeneration and death of cells in the macula, leading to the formation of sharply defined, well-demarcated areas of atrophy or cell loss. These areas appear as “geographic” patches of damaged retina, giving the condition its name. GA primarily affects central vision, impairing the ability to see fine details, read, drive, or recognize faces. The peripheral vision is typically preserved until later stages of the disease. Symptoms may include blurry or distorted central vision, decreased contrast sensitivity, and difficulty adapting to changes in lighting conditions. Diagnosis of geographic atrophy is typically based on a comprehensive eye examination, including retinal imaging such as optical coherence tomography (OCT) and fundus autofluorescence (FAF) imaging. Risk factors include advanced age, family history of AMD, smoking, and certain genetic factors.
For a complete picture of Geographic Atrophy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
